Bioanalytical Systems (BASI) Receives Daily Media Sentiment Score of 0.31
Media coverage about Bioanalytical Systems (NASDAQ:BASI) has been trending positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bioanalytical Systems earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.4430561576582 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Bioanalytical Systems (NASDAQ BASI) opened at $2.69 on Thursday. Bioanalytical Systems has a fifty-two week low of $0.65 and a fifty-two week high of $2.95. The company has a debt-to-equity ratio of 0.60, a current ratio of 0.64 and a quick ratio of 0.51.
TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/21/bioanalytical-systems-basi-receives-daily-media-sentiment-score-of-0-31.html.
Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.
Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with MarketBeat.com's FREE daily email newsletter.